Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of$0.10 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.12 per share when it actually produced a loss of$0.12, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Arbutus, which belongs to th ...